Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 89

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis

Gu, Jincui, Zhou, Yanbin, Huang, Lixia, Ou, Weijun, Wu, Jian, Li, Shaoli, Xu, Junwen, Feng, Jinlun, Liu, Baomo · 2016 · Molecular and Clinical Oncology

Abstract

A number of studies have examined the association between tumor protein 53 (TP53) mutations and the clinical outcome in patients with non-small-cell lung cancer (NSCLC), although these have yielded conflicting results. In the present study, electronic databases updated to September 2015 were searched to find relevant studies. A meta‑analysis was performed on the eligible studies, which quantitatively evaluated the association between the TP53 mutations and the survival of patients with NSCLC. Subgroup and sensitivity analyses were performed. A total of 19 studies that involved a total of 6,084 patients with NSCLC were included. When the TP53 mutation group (n=1,406) was compared with the wild-type group (lacking TP53 mutations; n=1,965), the wild‑type group was associated with a significantly higher overall survival rate [hazard ratio (HR), 1.26; 95% confidence interval (CI) 1.12‑1.41, P<0.0001]. Significant benefits of overall survival in the wild‑type group were found in the subgroup involving patients with NSCLC in the early stages, including the I/II phases (HR, 1.93, 95% CI, 1.17‑3.19, P=0.01; heterogeneity, I2=0.0%, P=0.976) and patients with adenocarcinoma (HR, 3.06; 95% CI, 1.66‑5.62, P<0.0001; heterogeneity: I2=0.0%, P=0.976). This meta‑analysis has indicated that TP53 gene alteration may be an indicator of a poor prognosis in patients with NSCLC. Furthermore, the results also suggested that the role of TP53 mutations may differ according to different pathological types and clinical stages. The presence of these mutations may define a subset of patients with NSCLC appropriate for investigational therapeutic strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/mco.2016.1057

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 47

  1. Jemal, 2008, Cancer statistics, 2008, CA Cancer J Clin, 58, 71, 10.3322/CA.2007.0010 · DOI · Paper page
  2. Ihde, 1991, Non-small cell lung cancer. Part II: Treatment, Curr Probl Cancer, 15, 105
  3. Farjah, 2009, Multi-modality mediastinal staging for lung cancer among medicare beneficiaries, J Thorac Oncol, 4, 355, 10.1097/JTO.0b013e318197f4d9 · doi:10.1097/jto.0b013e318197f4d9
  4. Goldstein, 2011, Understanding wild-type and mutant p53 activities in human cancer: New landmarks on the way to targeted therapies, Cancer Gene Ther, 18, 2, 10.1038/cgt.2010.63 · DOI · Paper page
  5. Singhal, 2005, Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review, Clin Cancer Res, 11, 3974, 10.1158/1078-0432.CCR-04-2661 · DOI · Paper page
  6. Toyooka, 2003, The TP53 gene, tobacco exposure, and lung cancer, Hum Mutat, 21, 229, 10.1002/humu.10177 · DOI · Paper page
  7. Greenblatt, 1994, Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis, Cancer Res, 54, 4855
  8. Steels, 2001, Role of p53 as a prognostic factor for survival in lung cancer: A systematic review of the literature with a meta-analysis, Eur Respir J, 18, 705, 10.1183/09031936.01.00062201 · DOI · Paper page
  9. Tsao, 2007, Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer, J Clin Oncol, 25, 5240, 10.1200/JCO.2007.12.6953 · DOI · Paper page
  10. Bodner, 1992, Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation, Oncogene, 7, 743
  11. Lohmann, 1993, Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives, Diagn Mol Pathol, 2, 36, 10.1097/00019606-199303000-00006 · DOI
  12. Harris, 1993, Clinical implications of the p53 tumor-suppressor gene, N Engl J Med, 329, 1318, 10.1056/NEJM199310283291807 · DOI · Paper page
  13. Mitsudomi, 2000, Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis, Clin Cancer Res, 6, 4055
  14. Huncharek, 2000, Prognostic significance of p53 mutations in non-small cell lung cancer: A meta-analysis of 829 cases from eight published studies, Cancer Lett, 153, 219, 10.1016/S0304-3835(00)00381-5 · DOI
  15. Kosaka, 2009, Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma, J Thorac Oncol, 4, 22, 10.1097/JTO.0b013e3181914111 · DOI · Paper page
  16. Fukuyama, 1997, K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer, Br J Cancer, 75, 1125, 10.1038/bjc.1997.194 · DOI
  17. Mitsudomi, 1993, Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer, J Natl Cancer Inst, 85, 2018, 10.1093/jnci/85.24.2018 · DOI · Paper page
  18. Tomizawa, 1999, Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma, Oncogene, 18, 1007, 10.1038/sj.onc.1202384 · DOI
  19. Lee, 2015, The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations, Mol Carcinog, 54, 93, 10.1002/mc.22077 · DOI
  20. Scoccianti, 2012, European Early Lung Cancer Consortium: Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort, Eur Respir J, 40, 177, 10.1183/09031936.00097311 · DOI
  21. Ma, 2014, Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer, Mol Oncol, 8, 555, 10.1016/j.molonc.2013.12.015 · DOI
  22. Chien, 2010, Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors, Ann Surg Oncol, 17, 1194, 10.1245/s10434-009-0853-2 · DOI
  23. Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 · DOI · Paper page
  24. Williamson, 2002, Aggregate data meta-analysis with time-to-event outcomes, Stat Med, 21, 3337, 10.1002/sim.1303 · DOI · Paper page
  25. Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics, 50, 1088, 10.2307/2533446 · DOI · Paper page
  26. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  27. Top, 1995, Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer, Int J Cancer, 64, 83, 10.1002/ijc.2910640203 · DOI
  28. Kashii, 1995, Evaluation of prognostic-significance of p53 gene alterations in patients with surgically resected lung-cancer, Int J Oncol, 6, 123
  29. Regina, 2009, Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN, Clin Chem, 55, 1834, 10.1373/clinchem.2009.123695 · DOI
  30. Huang, 1998, Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer, Int J Oncol, 12, 553
  31. Molina-Vila, 2014, Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer, Clin Cancer Res, 20, 4647, 10.1158/1078-0432.CCR-13-2391 · DOI · Paper page
  32. Vega, 1997, p53 Exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer, Br J Cancer, 76, 44, 10.1038/bjc.1997.334 · DOI
  33. Ahrendt, 2003, p53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study, J Natl Cancer Inst, 95, 961, 10.1093/jnci/95.13.961 · DOI · Paper page
  34. Mitsudomi, 1995, p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival, Ann Oncol, 6, S9, 10.1093/annonc/6.suppl_3.S9 · doi:10.1093/annonc/6.suppl_3.s9
  35. Ohno, 1997, p53 status and prognosis in stage I–IIIa non-small cell lung cancer, Int J Oncol, 10, 521
  36. Ludovini, 2008, Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: A study of the perugia multidisciplinary team for thoracic oncology, J Thorac Oncol, 3, 365, 10.1097/JTO.0b013e318168c7d0 · DOI
  37. Horio, 1993, Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer, Cancer Res, 53, 1
  38. Schiller, 2001, Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A laboratory ancillary study on an eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy, J Clin Oncol, 19, 448, 10.1200/JCO.2001.19.2.448 · DOI · Paper page
  39. Tolbert, 1999, p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status, Mod Pathol, 12, 54
  40. Meinhold-Heerlein, 2001, Evaluation of methods to detect p53 mutations in ovarian cancer, Oncology, 60, 176, 10.1159/000055316 · DOI
  41. Fong, 1995, Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer, Cancer Res, 55, 4268
  42. Sozzi, 1992, Deletions of 17p and p53 mutations in preneoplastic lesions of the lung, Cancer Res, 52, 6079
  43. Ahrendt, 2003, p53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study, J Natl Cancer Inst, 95, 961, 10.1093/jnci/95.13.961 · DOI · Paper page
  44. Poeta, 2007, TP53 mutations and survival in squamous-cell carcinoma of the head and neck, N Engl J Med, 357, 2552, 10.1056/NEJMoa073770 · DOI · Paper page
  45. Chiba, 1990, Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group, Oncogene, 5, 1603
  46. Soussi, 2001, Assessing TP53 status in human tumours to evaluate clinical outcome, Nat Rev Cancer, 1, 233, 10.1038/35106009 · DOI · Paper page
  47. Bria, 2015, Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma, Oncotarget, 6, 12783, 10.18632/oncotarget.3727 · DOI

Cited by

See all 89

Metadata

Authors
Gu, J., Zhou, Y., Huang, L., Ou, W., Wu, J., Li, S., Xu, J., Feng, J., & Liu, B.
Venue
Molecular and Clinical Oncology
Published
2016-10-21
Volume
5
Issue
6
Pages
705-713
ISSN
  • 2049-9450
  • 2049-9469
Cited by
89
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.